Yiping He

Journal Article Clin Cancer Res · October 15, 2025 PURPOSE: Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear. EXPERIMENTAL DESIGN: Using the recently developed purine short ... Full text Link to item Cite

Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.

Journal Article Prostate · March 2024 BACKGROUND: Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and has limited treatment options. Our previous stu ... Full text Link to item Cite

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Journal Article Nat Commun · January 25, 2024 Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. ... Full text Link to item Cite

View All Publications

Education, Training & Certifications

University of Pennsylvania · 2002 Ph.D.

Yiping He

Current Appointments & Affiliations

Recent Publications

Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress.

Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Recent Grants

The role of focal adhesion kinase in therapy resistant prostate tumors

ATRXmutations,innate immune activation and therapeutic vunerabilityin malignant gliomas

Glutaminase I isoforms as personalized biomarkers of prostate cancer

Education, Training & Certifications